QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

RYTM

QT47Rhythm Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
96.79
+0.96+1.00%
OverviewShort InterestFilings
RYTMQT47Rhythm Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
96.79+1.00%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-3.13
Insider Own1.47%
Shs Outstand68.53M
Perf Week10.42%
Market Cap6.57BForward P/E-EPS next Y-0.73Insider Trans0.54%Shs Float-Perf Month10.98%
Enterprise Value6.74BPEG2.64EPS next Q-0.82Inst Own-Short Float-Perf Quarter7.18%
Income-204430320.00P/S30.27EPS this Y0.09%Inst Trans-Short Ratio-Perf Half Y-13.93%
Sales217.17MP/B53.00EPS next Y76.69%ROA-45.82%Short Interest-Perf YTD-9.58%
Book/sh1.79P/C-EPS next 5Y-ROE-203.25%52W High122.19 -20.79%Perf Year56.19%
Cash/sh4.98P/FCF-EPS past 3/5Y-ROIC-56.40%52W Low60.70 59.46%Perf 3Y-
Dividend Est.-EV/EBITDA-37.28Sales past 3/5Y99.30% -Gross Margin89.41%Volatility4.51% 3.45%Perf 5Y-
Dividend TTM-EV/Sales31.03EPS Y/Y TTM27.88%Oper. Margin-90.89%ATR (14)4.57Perf 10Y-
Dividend Ex-Date-Quick Ratio3.89Sales Y/Y TTM66.92%Profit Margin-93.33%RSI (14)64.50Recom2.00
Dividend Gr. 3/5Y-Current Ratio4.17EPS Q/Q-2.47%SMA208.81%Beta1.14Target Price139.57
Payout0.00%Debt/Eq1.85Sales Q/Q81.82%SMA509.54%Rel Volume2.15Prev Close95.83
Employees283LT Debt/Eq1.71EarningsAug 04SMA200-1.00%Avg Volume725.89KPrice96.79
IPO DateOct 09, 2017Option/ShortYes / YesEPS/Sales Surpr.3.49% 7.14%Net Debt/EBITDA-0.91Volume1,558,443Change1.00%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-16-26ReiteratedCanaccord GenuityBuy$143 → $151
Jun-15-26ReiteratedStifel NicolausBuy$131 → $133
Jun-15-26ReiteratedWells FargoOverweight$143 → $155
May-07-26ReiteratedCanaccord GenuityBuy$141 → $143
Mar-12-26ReiteratedTelsey Advisory$143
Mar-12-26ReiteratedWells FargoOverweight$145 → $143
Mar-03-26ReiteratedJefferies$80 → $125
Feb-26-26ReiteratedStifel NicolausBuy$78 → $131
Feb-18-26ReiteratedRBC Capital$145
Jan-20-26ReiteratedH.C. Wainwright$123 → $125
Latest News
Jun-17-26
Jun-17-2612:02PM
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome - SlideshowSeekingAlpha
12:02PM
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome TranscriptSeekingAlpha
Jun-16-26
Jun-16-2603:37PM
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesityYahoo
11:54AM
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $151Benzinga
Jun-15-26
Jun-15-2609:10PM
The Battle Against Genetic Obesity Just Sent This Biotech Stock FlyingYahoo
08:01PM
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026Yahoo
04:04PM
Rhythm Pharmaceuticals Presents Data From Multiple Presentations At Endocrine Society's Annual MeetingBenzinga
12:51PM
Why Is Rhythm Pharma Stock Jumping Today?Benzinga
09:04AM
Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $155Benzinga
03:17AM
Reported Saturday, Rhythm Pharmaceuticals Presents Phase 2 Data Showing Setmelanotide Achieves 3.06% Mean BMI Reduction And Clinically Meaningful Hyperphagia Improvements In Prader-Willi Syndrome Patients At ENDO 2026Benzinga
Jun-13-26
Jun-13-2612:01PM
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026Yahoo
Jun-12-26
Jun-12-2608:01PM
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi SyndromeYahoo
04:02PM
Rhythm Pharmaceuticals To Present Interim Phase 2 Setmelanotide Data In Prader-Willi Syndrome On June 13 At 9:00 a.m. ETBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue217190130
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A231913
Gross Profit194170117
Selling, General and Administrative Excl. Other219195144
Research and Development172167238
Other Operating Expense000
Operating Income-197-192-266
Interest Expense212121
Unusual Expense
———
Non-Operating Income (Expense)-16-17-26
Net Income Before Taxes-202-196-260
Income Taxes100
Consolidated Net Income-204-197-261
Net Income From Continuing Operations-204-197-261
Net Income-204-197-261
EPS (Recurring)-3.13-3.11-4.34
EPS (Basic, Before Extraordinaries)-3.13-3.11-4.34
EPS (Diluted)-3.13-3.11-4.34
EBITDA-181-174-238
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio30.3336.62—
Gross Margin89.4089.4790.00
Operating Margin-90.78-101.05-204.62
Net Margin-94.01-103.68-200.77
Shares Outstanding686561
Market Capitalization6,5826,958—
Operating Lease Expense
———
Insider Trading Volume
$108.94$96.24$83.54$70.84$58.14● Close Price0.00M1.93M3.86M5.79M7.72MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Smith Hunter CChief Financial OfficerMay 18 '26Option Exercise17.876,000107,220119,611May 20 12:00 AM
German Christopher PaulCorporate Controller & CAOMay 15 '26Option Exercise42.178,884374,6264,643May 19 12:00 AM
German Christopher PaulCorporate Controller & CAOMay 15 '26Sale92.214,643428,1310May 19 12:00 AM
Mazabraud YannEVP, Head of InternationalApr 01 '26Option Exercise0.0025,750066,030Apr 03 12:00 AM
German Christopher PaulCorporate Controller & CAOMar 04 '26Option Exercise17.973,00053,9105,753Mar 06 12:00 AM
German Christopher PaulCorporate Controller & CAOMar 04 '26Sale89.565,614502,790160Mar 06 12:00 AM
German Christopher PaulCorporate Controller & CAOMar 01 '26Option Exercise0.002,32404,595Mar 03 12:00 AM
Smith Hunter CChief Financial OfficerMar 02 '26Option Exercise6.8012,19882,946116,611Mar 02 12:00 AM
Smith Hunter CChief Financial OfficerFeb 19 '26Sale101.264,385444,004110,512Feb 19 12:00 AM
Smith Hunter CChief Financial OfficerFeb 17 '26Sale101.383,569361,810114,897Feb 19 12:00 AM
Mazabraud YannEVP, Head of InternationalFeb 14 '26Option Exercise0.0020,000053,155Feb 18 12:00 AM
Smith Hunter CChief Financial OfficerFeb 12 '26Sale98.231,592156,380118,466Feb 12 12:00 AM
Smith Hunter CChief Financial OfficerFeb 11 '26Sale98.612,766272,766120,058Feb 12 12:00 AM
Smith Hunter CChief Financial OfficerFeb 10 '26Sale103.002,713279,430122,824Feb 12 12:00 AM
Smith Hunter CChief Financial OfficerFeb 05 '26Sale106.063,381358,599125,537Feb 06 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR